Paper Details

  1. Home
  2. Paper Details

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.

Author: GuptaSuneel, LamAndrew, LernerMarc, LindemulderElizabeth, ModiNishit, ShoulsonIra, SwansonJames, WigalSharon

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study reviewed the development of sustained-release formulations of methylphenidate, a medication for ADHD, and explored the reasons for their reduced efficacy compared with immediate-release formulations. Tachyphylaxis, or a rapid decrease in response to a drug, was hypothesized to be a contributing factor.
Paper Details　
Original Abstract of the Article :
The duration of action of the immediate-release formulation of methylphenidate hydrochloride is short (3 to 4 hours), and 3 times daily dosing is thought to maximize effectiveness across a 12-hour day. The initial sustained-release formulations of methylphenidate had reduced efficacy compared with i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/archpsyc.60.2.204

データ提供：米国国立医学図書館（NLM）

Methylphenidate: A New Oasis for ADHD Treatment

Attention-deficit/hyperactivity disorder (ADHD) presents a significant challenge for individuals and their families. This study, like a determined camel seeking the best route through the vast desert of ADHD research, explores the development of a new once-a-day formulation of methylphenidate, a commonly prescribed medication for ADHD. The authors conducted proof-of-concept and proof-of-product studies to evaluate the efficacy and safety of this novel formulation.

A New Path: Developing a More Convenient Treatment for ADHD

This research highlights the development of a new once-a-day formulation of methylphenidate, aimed at improving the convenience and effectiveness of ADHD treatment. The authors address the challenges associated with existing formulations, including the short duration of action and the need for multiple daily doses.

Finding the Right Balance: Managing ADHD with Medication

When considering medication for ADHD, it's essential to work closely with a healthcare professional to determine the most appropriate treatment approach. Medication can be a valuable tool in managing ADHD symptoms, but it's often combined with other therapies, such as behavioral therapy, to achieve the best possible outcomes.

Dr.Camel's Conclusion

This study offers hope for individuals with ADHD seeking more convenient and effective treatment options. The development of a new once-a-day formulation of methylphenidate could significantly improve the quality of life for those managing this condition. As with navigating a challenging desert landscape, finding the right path to managing ADHD requires careful consideration and a collaborative approach with your healthcare team.

Date :
  1. Date Completed 2003-03-04
  2. Date Revised 2019-07-17
Further Info :

Pubmed ID

12578439

DOI: Digital Object Identifier

10.1001/archpsyc.60.2.204

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.